1. Home
  2. WPP vs ACAD Comparison

WPP vs ACAD Comparison

Compare WPP & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WPP plc

WPP

WPP plc

HOLD

Current Price

$17.59

Market Cap

3.6B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.73

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WPP
ACAD
Founded
1985
1993
Country
United Kingdom
United States
Employees
103277
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.8B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
WPP
ACAD
Price
$17.59
$22.73
Analyst Decision
Hold
Buy
Analyst Count
2
22
Target Price
N/A
$30.55
AVG Volume (30 Days)
504.7K
1.4M
Earning Date
03-19-2026
05-06-2026
Dividend Yield
12.02%
N/A
EPS Growth
N/A
69.12
EPS
N/A
2.30
Revenue
N/A
$726,437,000.00
Revenue This Year
N/A
$18.80
Revenue Next Year
$4.32
$11.70
P/E Ratio
$38.96
$9.87
Revenue Growth
N/A
40.45
52 Week Low
$14.81
$14.20
52 Week High
$40.95
$28.35

Technical Indicators

Market Signals
Indicator
WPP
ACAD
Relative Strength Index (RSI) 55.76 56.45
Support Level $17.36 $19.87
Resistance Level $19.55 $22.97
Average True Range (ATR) 0.47 0.65
MACD 0.04 0.11
Stochastic Oscillator 56.27 97.81

Price Performance

Historical Comparison
WPP
ACAD

About WPP WPP plc

Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: